Axol Bioscience - September Newsletter

This month's highlights

• Have you ever been faced with a "head vs heart" situation? This month at Axol Bioscience, we've been thinking about both! With September bringing World Alzheimer's Awareness Month (and Day) 2023, we've had a busy month of activities related to iPSC-derived neurons and neuroinflammatory cells, such as our Alzheimer's Webinar (see below).
• September has also featured World Heart Day 2023 and Atrial Fibrillation Awareness, so we also ran a webinar diving into the data behind our high-quality, chamber-specific cardiomyocytes (see below).
• Work continues towards collaborating on advanced iPSC model systems across major therapy areas, and with this, we launched our axoModelsTM offering. We're offering our iPSC expertise to collaboratively build robust in vitro models to generate data for compounds. If you'd like to discuss working together, get in touch: Contact us for iPSC derived cells and service | Axol Bioscience

Webinar: Building chamber-specific human cardiac models with iPSCs

In the same month where we've recognized Atrial Fibrillation Awareness and World Heart Day, our Senior Scientific Support Manager Dr. Steven Broadbent took us through the topic of "Building chamber-specific?human cardiac models with?iPSCs".

Make sure to download the recording to hear Dr Broadbent's wisdom on:

• The growing need for better cardiac safety models (and why current models aren't working)
• The data behind Axol Bioscience's world-leading iPSC-derived cardiomyocytes
• How to build robust, chamber-specific cardiac models

With a useful Q+A discussion (and excellent feedback from attendees), we're making the webinar available to download- simply to access:

Axol Bioscience Webinars

Netri announce new product range powered by axoCells?

We’re excited to see the launch of Netri's new organ-on-chip (OOC) range , which will be powered by?axoCells iPSC-derived sensory neurons , combining the?quality and consistency?of Axol’s sensory neurons with NETRI’s OOC capabilities.

These new OOC kits will provide robust?in vitro?models of the peripheral nervous system in a?high-throughput format, enabling the generation of?larger, faster, and more predictive datasets. With enormous industry interest behind OOC platforms, this collaboration will further drive the adoption of OOCs in biopharma, which will hopefully translate to improved research and drug discovery in neuroscience.

With over a decade of experience in the iPSC industry, we're now able to manufacture high-quality, reproducible iPSC-derived cells at scale. As a result, we are actively engaging with platform providers to supply our axoCells as a?critical quality component?for advanced in vitro platforms, and we’re currently partnering with a growing list of providers looking to have their platforms "powered by axoCells".

Click to read more about this exciting announcement:

NETRI launch new organ-on-chip kit powered by axoCells ( axolbio.com )

Webinar: Tackling the 99.6% Alzheimer's problem

Couldn't make our latest webinar? Don't miss out on our expert discussion on how we're using human iPSCs to drive Alzheimer's Disease drug discovery to tackle the 99.6% failure rate. Hosted by?our Product Manager, Jan Turner, and StrataStem Co-Founder/CSO Chris Ward, the webinar covered a range of topics, including:

• The driving factors behind the 99.6% failure rate in drug discovery
• Current challenges to address for in vitro models of Alzheimer's Disease
• Components of a successful "clinical trial in a dish " model for Alzheimer's Disease
• The exciting applications of a cohort-scale model to stratify patients for later-stage clinical trials

With thought-provoking discussions and insightful audience questions, this is a must-watch for anyone in the drug discovery, neurodegenerative research, or iPSC space.

Click to download the recording: Axol Bioscience Webinars

Ushio selects Axol as its critical supplier of iPSC-derived sensory neuron cells.

We're delighted to announce that Ushio Inc ., a world-class provider of organ-on-chip platforms for pre-clinical neuroscience discovery, will power their advanced? in vitro ?Nerve Plate platform with highly functional human iPSC-derived axoCells?sensory neurons.

Fueled by our functionally relevant, consistent neurons, Ushio's platform will serve as a simpler and more powerful neurotoxicity model for the pharmaceutical industry. This will be in conjunction with Professor Ikuro Suzuki from the Tohoku Institute of Technology , whose AI technology will enable high-throughput quantitative prediction of nerve disorder risks.

We're excited to see the applications of this novel platform in driving a deeper understanding of the peripheral nervous system and identifying potential therapeutics for disorders of pain, sensation, and neurodegeneration.

This agreement also continues our progress as a critical quality supplier to industry platform providers, made possible by the quality, consistency, and expertise behind the axoCells offering.

Read more about it here: Ushio Inc. selects Axol as its critical quality supplier of iPSCs ( axolbio.com )

Introducing our new axoModels? webpage

After more than a decade of engaging with biopharma organizations and conducting market research, we've identified a clear need for physiologically-relevant models to test potential therapeutics in the early pre-clinical stage. Generating in vitro data is no longer a luxury, it's a necessity (read this market trends piece to find out why), but high-quality iPSCs can be hard to source and technically challenging.

That's why we've launched axoModels to partner with biopharma organizations who are looking to exploit iPSC test model systems for pre-clinical compound screening. Using our iPSC expertise, we collaboratively build, assess, and execute model systems powered by functional, consistent axoCells. In essence, we handle the difficult technical aspects, letting our partners focus on the science and data to drive drug discovery pipelines.

To explore a typical project set-up and get a deeper understanding, take a look at our new axoModels webpage here: axoModels? - iPSC-based systems for compound screening | AXOL Bioscience

Infographic: Our commitment to quality and consistency

As a company that values consistency, quality, and scientific rigor, we have a long-standing history of meeting and exceeding industry best practices. Our production facility in Roslin is the heart of our manufacturing and logistics capabilities, where we produce high-quality, high-performing iPSC products with an emphasis on consistency and scalability.

We've produced this infographic to outline the impressive numbers behind our manufacturing and logistics facility in Roslin, including:

• Our impressive manufacturing capabilities
• Delivery and logistics excellence
• The experience and technical expertise that drives our performance
• Our global commercial reach

Click the link to download the infographic: https://axolbio.com/wp-content/uploads/2023/10/AXOL-Quality-Infographic-2023.pdf